Figure 3. Changes in neutrophil count in patients treated with bleomycin, etoposide and cisplatin during cycles using pegfilgrastim (Peg) andfilgrastim (Fil). A: Maximum neutrophil count for individual patients. Bars represent median values. B: The number of days to the maximumneutrophil count for individual patients. C: The percentage of patients with maximum neutrophil count before and after initiation of granulocytecolonystimulating factor (G-CSF) is shown. Most maximum neutrophil counts were recorded on days after pegfilgrastim injection in cyclesadministering pegfilgrastim; however, only half of the maximum neutrophil counts were recorded after filgrastim injection in cycles administeringfilgrastim. D: Of cycles with maximum neutrophil count recorded before initiation of G-CSF, the percentage of cycles with maximum count beforeG-CSF initiation in the first and subsequent (second, third, and fourth) cycles in the therapy series of bleomycin, etoposide, and cisplatin is shown.